

Ref: BHL/STEX 44/ 2026-27

Date: October 17, 2026

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400001 Scrip Code: 539872	National Stock Exchange of India Limited 5 th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051 Symbol: BAJAJHCARE
--	--

Sub: Outcome of the Board Meeting held on October 17, 2026

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations") we hereby inform you that the Board of Directors of our Company at its meeting held today i.e. October 17, 2026, has considered and approved the Un-audited Standalone Financial Results of the Company for the quarter and half year ended September 30, 2026 along with the Limited Review Report thereon issued by Walker Chandiok & Co. LLP, Chartered Accountants, Statutory Auditors of the Company in accordance with the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the same is attached herewith.

We wish to inform you that the Board Meeting commenced today at 4.00 p.m. and concluded at 4:24 p.m.

Kindly take the same on record.

Thanking you.

Yours faithfully,

For and on behalf of Bajaj Healthcare Limited

MONICA TANWAR
Digitally signed by
MONICA TANWAR
Date: 2026.10.17
16:59:30 +05'30'

Monica Tanwar
Company Secretary & Compliance Officer

Encl: as above

Walker ChandioK & Co LLP

16th Floor, Tower III,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India
T +91 22 6626 2600

Independent Auditor's Review Report on Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Bajaj Healthcare Limited

1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **Bajaj Healthcare Limited** ('the Company') for the quarter ended **30 September 2026** and the year to date results for the period 01 April 2026 to 30 September 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Bajaj Healthcare Limited

Independent Auditor's Review Report on Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013



Yashwant M. Jain

Partner

Membership No. 118782

UDIN:- 26118782ILCZXK5585

Place: Mumbai

Date: 17 October 2026

BAJAJ HEALTHCARE LIMITED

(CIN No.: L99999MH1993PLC072892)

(Reg. and Corp. Office: 602-606, 6th Floor, Bhoomi Velocity Infotech Park, Above ICICI Bank, Road No. 23, Wagle Industrial Estate, Thane (W) - 400 604)
(Tel: + 91-22-6617400, Email: investors@bajajhealth.com, Website: www.bajajhealth.com)

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2026

(Rs. In Lakhs except for Earnings Per Share)

Particulars	Quarter Ended			Period ended		Year Ended
	30 Sept 2026	30 June 2026	30 Sept 2025	30 Sept 2026	30 Sept 2025	31 March 2026
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
A. Continuing operations						
I. Revenue from operations	17,590.16	16,563.17	14,791.49	34,153.33	29,675.12	61,103.14
II. Other income	89.24	81.14	165.29	170.38	253.06	713.39
III. Total income (I+II)	17,679.40	16,644.31	14,956.78	34,323.71	29,928.18	61,816.53
IV. Expenses						
(a) Cost of materials consumed	9,841.21	9,158.91	7,480.50	19,000.12	14,468.99	30,619.95
(b) Changes in inventories of finished goods and work-in-progress	(703.96)	(549.24)	(120.39)	(1,253.20)	949.92	1,019.54
(c) Employee benefits expense	1,911.21	1,747.12	1,650.87	3,658.33	3,086.49	6,275.26
(d) Finance costs	597.53	609.10	555.87	1,206.63	1,078.44	2,223.37
(e) Depreciation and amortisation expense	764.94	701.38	708.21	1,466.32	1,271.86	2,754.84
(f) Other expenses	3,420.88	3,331.21	3,085.51	6,752.09	6,023.76	12,706.61
Total expenses	15,831.81	14,998.48	13,360.57	30,830.29	26,879.46	55,599.57
V. Profit before exceptional items and tax expense	1,847.59	1,645.83	1,596.21	3,493.42	3,048.72	6,216.96
VI. Exceptional items	-	-	-	-	-	(3,324.66)
VII. Profit before tax	1,847.59	1,645.83	1,596.21	3,493.42	3,048.72	2,892.30
VIII. Tax expense						
(a) Current tax	-	-	-	-	-	-
(b) Deferred tax	409.61	256.55	351.35	666.16	586.49	761.26
Total tax expense	409.61	256.55	351.35	666.16	586.49	761.26
IX. Profit after tax from continuing operations	1,437.98	1,389.28	1,244.86	2,827.26	2,462.23	2,131.04
B. Discontinued operations						
X. Loss before tax from discontinued operations (Refer note 4)	(38.19)	(26.03)	(179.00)	(64.22)	(224.43)	(511.69)
XI. Tax impact of discontinued operations	(9.61)	(6.55)	(45.06)	(16.16)	(56.49)	42.74
XII. Loss after tax from discontinued operations	(28.58)	(19.48)	(133.94)	(48.06)	(167.94)	(554.43)
XIII. Profit for the period / year (IX + XII)	1,409.40	1,369.80	1,110.92	2,779.20	2,294.29	1,576.61
XIV. Other comprehensive income						
Continuing operations						
(i) Items that will not be reclassified to profit or loss						
- Remeasurement of defined benefit plans	30.00	30.00	25.00	60.00	50.00	81.49
(ii) Income tax relating to items that will not be reclassified to profit or loss	(7.55)	(7.55)	(6.30)	(15.10)	(12.59)	(20.51)
Total Other comprehensive income from continuing operations	22.45	22.45	18.70	44.90	37.41	60.98
Discontinued operations						
(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
Total Other comprehensive income from discontinued operations	22.45	22.45	18.70	44.90	37.41	60.98
Other comprehensive income for the period / year	22.45	22.45	18.70	44.90	37.41	60.98
XV. Total comprehensive income for the period / year (XIII + XIV)	1,431.85	1,392.25	1,129.62	2,824.10	2,331.70	1,637.59
XVI. Paid-up equity share capital (Face Value Rs. 5 per share)	1,683.26	1,683.13	1,579.16	1,683.26	1,579.16	1,683.13
XVII. Other equity						51,617.10
XVIII. EPS (Not Annualised except for the year ended 31 March 2026)						
Continuing operations						
(a) Basic EPS (in Rs.)	4.27	4.13	3.95	8.40	7.80	6.73
(b) Diluted EPS (in Rs.)	4.26	4.12	3.88	8.38	7.63	6.72
Discontinued operations						
(a) Basic EPS (in Rs.)	(0.08)	(0.06)	(0.42)	(0.14)	(0.53)	(1.75)
(b) Diluted EPS (in Rs.)	(0.08)	(0.06)	(0.41)	(0.14)	(0.52)	(1.75)
Total operations						
(a) Basic EPS (in Rs.)	4.19	4.07	3.53	8.26	7.27	4.98
(b) Diluted EPS (in Rs.)	4.18	4.06	3.47	8.24	7.11	4.97



[Handwritten signature]



BAJAJ HEALTHCARE LIMITED
(CIN No.: L99999MH1993PLC072892)

BALANCE SHEET AS AT 30 SEPTEMBER 2026

Particulars	(Rs. in Lakhs)	
	As at 30 Sep 2026 (Unaudited)	As at 31 Mar 2026 (Audited)
A ASSETS		
1 Non-current assets		
(a) Property Plant & Equipment	22,837.53	21,755.52
(b) Right of Use Assets	2,781.12	2,966.96
(c) Capital Work in Progress	1,066.49	794.14
(d) Other Intangible Assets	640.29	98.18
(e) Intangible Assets Under Development	-	-
(f) Financial Assets		
i) Investments	2.02	0.33
ii) Other Financial Assets	1,323.49	1,369.62
(g) Non current tax Assets (Net)	439.91	370.74
(h) Deferred tax Assets (Net)	399.91	1,065.01
(i) Other non current assets	4,183.76	2,250.00
Total Non Current Assets	33,674.52	30,670.50
2 Current assets		
(a) Inventories	23,653.40	21,600.96
(b) Financial Assets		
(i) Trade receivables	25,162.53	23,385.38
(ii) Cash and cash equivalents	1,347.32	3,723.54
(iii) Bank Balance other than (ii) above	74.67	75.19
(iv) Other Financial assets	846.37	522.67
(c) Other Current Assets	6,143.94	5,350.48
Total Current assets	57,228.23	54,658.22
Non Current assets classified as Held for sale	7,212.06	6,993.00
Total Assets	98,114.81	92,321.72
B EQUITY AND LIABILITIES		
1 Equity		
(a) Share Capital	1,683.26	1,683.13
(b) Other Equity	54,032.85	51,617.10
Total Equity	55,716.11	53,300.23
2 Liabilities		
Non-Current Liabilities		
(a) Financial Liabilities		
i) Borrowings	7,038.06	4,756.57
ii) Lease Liabilities	1,094.52	1,263.91
(b) Provisions	807.85	717.85
Total Non-Current Liabilities	8,940.43	6,738.33
3 Current Liabilities		
(a) Financial Liabilities		
i) Borrowings	19,713.71	18,589.77
ii) Lease Liabilities	319.96	298.83
iii) Trade Payables		
Total outstanding dues of Micro and Small enterprises	452.56	654.12
Total outstanding dues of creditors other than Micro and Small enterprises	10,694.85	10,873.87
iv) Other Financial Liabilities	1,110.18	350.06
(b) Other Current Liabilities	116.38	122.11
(c) Provisions	32.22	102.40
Total Current Liabilities	32,439.86	30,991.16
Liabilities Associated with Assets held for sale	1,018.41	1,292.00
Total Liabilities	42,398.70	39,021.49
Total Equity and Liabilities	98,114.81	92,321.72



For and on behalf of the Board
For Bajaj Healthcare Limited

Anil Champatal Jain
DIN : 00226137
Managing Director


Date : 17 October 2026
Place: Thane

BAJAJ HEALTHCARE LIMITED
(CIN No.: L99999MH1993PLC072892)

STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED 30 SEPTEMBER 2026

(Rs. in Lakhs)

Particulars	As at 30 Sept 2026 (Unaudited)	As at 30 Sept 2025 (Unaudited)
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit/(Loss) before tax	3,429.20	2,824.29
From Continuing operations	3,493.42	3,048.72
From Discontinued operations	(64.22)	(224.43)
Adjustments for:		
Depreciation and amortisation expense	1,466.32	1,271.86
Profit on sale of Property Plant & Equipment	(95.88)	0.08
Finance Cost	1,206.63	1,078.44
Interest on Fixed deposits	(16.38)	(29.93)
Unrealised Foreign Exchange Gain (Net)	(118.75)	-
Exceptional item	-	(215.92)
Share Based Compensation Expenses	96.63	7.05
Allowance for expected credit loss	350.00	200.00
Operating Profit before Working Capital Changes	6,317.77	5,135.87
Adjustments for:		
(Increase)/Decrease in Non-Current and Current Assets	(1,072.72)	(227.68)
(Increase)/Decrease In Trade receivable	(2,153.59)	1,989.66
(Increase)/Decrease In Inventories	(2,052.44)	558.01
Increase in trade payables	(380.58)	(1,268.05)
Increase in non-current and current liabilities and provisions	964.30	(1,114.44)
Cash generated from operations	1,622.74	5,073.37
Income Tax paid (net of refunds)	(54.07)	(54.83)
Net Cash flow from Operating activities (A)	1,568.67	5,018.54
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property Plant and Equipment (including capital work-in-progress, capital advances and other intangible assets)	(6,096.25)	(1,098.42)
Proceeds from sale of Property Plant & Equipment	756.02	12.50
Interest received on Fixed Deposits	16.38	29.93
Amount paid for investment in Genrx	-	(810.00)
Redemption of fixed deposits	153.35	(18.14)
Investment in fixed deposits	(152.83)	(95.88)
Net Cash used in Investing activities (B)	(5,323.33)	(1,980.01)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Issue of Shares	0.13	-
Repayment of Long Term Borrowing	(1,270.38)	(992.42)
Proceeds from Long Term Borrowing	3,577.64	96.15
Proceeds/(Repayment) of Short Term Borrowing (net)	925.67	(48.59)
Principal payment of lease liabilities	(143.01)	(77.94)
Interest payment of lease liabilities	(62.54)	(26.74)
Interest paid, other than lease liabilities	(1,144.09)	(1,051.70)
Dividend Paid	(504.98)	-
Net Cash (used in) / from financing activities (C)	1,378.44	(2,101.24)
Net increase in Cash & Cash Equivalents (A+B+C)	(2,376.22)	937.29
Cash and Cash equivalents at the beginning of the period	3,723.54	260.38
Cash and Cash equivalents at the end of the period	1,347.32	1,197.67



For and on behalf of the Board
For Bajaj Healthcare Limited

Anil Champalal Jain
Anil Champalal Jain
DIN : 00226137
Managing Director

Date : 17 October 2026
Place: Thane

Notes :

1. The above financial results of Bajaj Healthcare Limited (the 'Company') have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 17 October 2026. These results have been subjected to a limited review by the statutory auditors who have expressed an unmodified review conclusion.

2. The above un-audited financial results for the quarter and half year ended 30 September 2026 have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standards (Ind AS), as prescribed under Section 133 of the Companies Act 2013 (Act) read with relevant rules issued thereunder and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

3. The Company deals in pharmaceuticals products (formulations and active pharmaceutical ingredients components) which are interlinked and interdependent. Therefore, the Company has identified only one reportable segment i.e. Pharmaceuticals.

4. In the year ended 31 March 2024, the Board of Directors had approved to sale/disposal of undertaking/unit(s) on going concern basis, situated at plot no. N-92, L-9/3, T-30, MIDC Tarapur, Taluka- Boisar, District Palghar, Maharashtra and vacant industrial land situated at plot no. D-2/CH/42 & D-2/CH/43 Dahej industrial area, GIDC, Bharuch, Gujarat (which were acquired under SARFAESI ACT, 2022 from Saraswat Bank) and plot no.E-62 and E-63 MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra. The approval of shareholders was obtained vide postal ballot. The Company has classified the assets and liabilities in relation to these units as Assets and liabilities held for sale/disposal under Ind AS 105 ("Non-current Assets Held for Sale and Discontinued Operations"). The results of the operation of these units have been presented separately on the Statement of Profit and Loss as Discontinued Operations. Out of these, one unit situated at plot no. N-92 was sold during the Quarter ended 31 March 2024 and L-9/3 was sold during the Quarter ended 31 March 2026. The Company has sold a portion of its Plot No. D-2/CH/42 & D-2/CH/43 Dahej Industrial Area, GIDC, Bharuch, Gujarat in the current quarter. The total value of assets classified as held for sale represents lower of carrying value or fair value.

The financial information from discontinued operations:

Particulars	Quarter Ended			Period ended		Year ended
	30 Sept 2026	30 June 2026	30 Sept 2025	30 Sept 2026	30 Sept 2025	31 March 2026
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total Income (A)	75.35	-	0.05	75.35	2.15	11.71
Total Expenses (B)	113.54	26.03	179.05	139.57	226.58	523.40
Loss before Tax from Discontinued Operations (C = A - B)	(38.19)	(26.03)	(179.00)	(64.22)	(224.43)	(511.69)
Tax Credit from Discontinued Operations (D)	(9.61)	(6.55)	(45.06)	(16.16)	(56.49)	42.74
Loss after Tax from Discontinued Operations (E = C - D)	(28.58)	(19.48)	(133.94)	(48.06)	(167.94)	(554.43)

Subsequent to the quarter ended 30 September 2026, the Company has completed its sale of Plot No. D-2/CH/42 & D-2/CH/43 Dahej Industrial Area, GIDC, Bharuch, Gujarat.

5. On 23 June 2026, the Board of Directors of the Company approved the sale of its unit at Plot No. N-178, MIDC, Tarapur Industrial Area, Tarapur, Boisar, Palghar 401 506 with an unrelated party. The expected timeline for conclusion of Sale transaction is 31 October 2026. Hence, the unit has been classified as Property Held for Sale as at 30 September 2026.

6. During the financial year ended 31 March 2025, the Company allotted 39,84,852 equity shares and 20,79,409 convertible warrants on a preferential basis, raising an aggregate amount of Rs. 20,497.00 lakhs. The consideration for the equity shares was received in September 2024, and the shares were allotted in the same month. Further, 25% of the issue price of the convertible warrants was received in September 2024, and the balance 75% was received in March 2026. Subsequently, in March 2026, the Company approved the conversion of all 20,79,409 convertible warrants into an equivalent number of fully paid-up equity shares of face value Rs. 5 each.

The fund raised through allotment of equity shares and convertible warrants under the preferential issue has been utilised for following activities:

Particulars	Amount to be Utilised	Utilised up to 30 Sept 2026	Unutilised Balance
Repayment of loan	15,000.00	15,000.00	-
Investment in capital expenditure	3,500.00	2,912.48	587.52
General corporate purposes	1,997.00	1,993.48	3.52
Total	20,497.00	19,905.96	591.04

7. In April 2025, the Company acquired Genrx Pharmaceuticals Private Limited (in Liquidation) ("Genrx"), an existing company incorporated under the provisions of the Companies Act, 1956, on a going concern basis for a total consideration of ₹1,085.00 lakhs.

Subsequently, on 3 June 2025, the Company filed an application before the Hon'ble National Company Law Tribunal ("NCLT"), Mumbai Bench, seeking certain reliefs and concessions necessary for the effective implementation of the acquisition and takeover of Genrx as a going concern. The said application remained pending before the NCLT as on 30 September 2026. Accordingly, Genrx has not been considered a subsidiary of the Company for consolidation purposes, as control, as defined under Ind AS 110, Consolidated Financial Statements, had not been established as at the reporting date.

However, on 13 October 2026, the Company received an order from the Hon'ble NCLT approving the acquisition of Genrx on a going concern basis.

Pursuant to the aforesaid order, Genrx Pharmaceuticals Private Limited will become a wholly owned subsidiary of Bajaj Healthcare Limited, subject to the implementation of the terms and conditions specified in the order passed by the Hon'ble NCLT and the completion of the applicable procedural and legal formalities.



Date : 17 October 2026

Place: Thane

For and on behalf of the Board
For Bajaj Healthcare Limited

Anil Chempal Jain
DIN : 00226137
Managing Director

